Teva Pharmaceutical Industries Limited's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Teva Pharmaceutical Industries Limited's ROA in the second quarter of 2026?
Teva Pharmaceutical Industries Limited achieved a return on average assets (ROA) of 1.51 % in its second quarter of 2026, this is above TEVA's average return on assets of -0.24%.
Teva Pharmaceutical Industries Limiteds assets during the 12 months ending in the second quarter of 2026 are valued at $47 billion

ROA decreased relative to the period ending Mar 31 2026, due to the decline in net income.

However, within the Healthcare sector 194 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 1399, from total ROA ranking in the first quarter of 2026 at 1721.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-16.73 %	6.53 %	11.09 %	0.14 %	1.56 %
Y / Y Net Income Change	-	67.73 %	-	-	-
Net Income (TTM) in million	709	1,567	1,418	661	-163
Return On Assets (TTM)	1.51 %	3.2 %	2.94 %	1.41 %	-0.35 %
TEVA's Total Ranking	# 1399	# 1721	# 1930	# 2640	# 2945
Total Assets (TTM) in million	39,857	48,696	51,463	48,023	47,867
Seq. Total Assets Change	-18.15 %	-5.38 %	7.16 %	0.33 %	4.72 %
Seq. Net Income Change	-	-23.28 %	10.83 %	53.36 %	28.64 %

TEVA's 5 Years Annual ROA >> Back to TEVA Management Effectiveness >> Compare TEVA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 68
Sector	# 195
Overall	# 1877

Return On Assets Statistics
High	Average	Low
9.12 %	-0.24 %	-20.44 %
(Dec 31 2010)		(Mar 31 2018)

News about Teva Pharmaceutical Industries Limited Return on Assets ROA

Teva Pharmaceuticals Strategic Shift Pays Off: Fitch Upgrades Rating Amid Promising Duvakitug Developments

In a notable development for Teva Pharmaceuticals, Fitch Ratings Agency has upgraded the company s rating to BB+, acknowledging its effective pivot towards a growth strategy that has begun to bear fruit. This strategic transformation, coupled with the recent promising data from the Phase 2b clinical trial of Duvakitug, Teva’s innovative therapy in partnership with Sanofi for autoimmune diseases such as Ulcerative Colitis (UC) and Crohn’s Disease (CD), paints a compelling picture of the company’s potential in the evolving pharmaceutical landscape.Teva s upgraded rating reflects a broader recognition of its efforts to navigate challenging market conditions while revitalizing its portfolio and operational efficiencies. Fitch highlighted that the company s pivotal shift includes a stronger focus on innovation, specifically targeting areas with high unmet medical needs, thereby positioning Teva to emerge as a leader in the competitive biopharmaceutical sector.

Financial Statements
Teva Pharmaceutical Industries Limited's Assets	$ 39,857 million	TEVA's Balance sheet
Teva Pharmaceutical Industries Limited's Income	$ -575 million	Quarterly TEVA's Income Statement
TEVA's Income by Division		See TEVA's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	11.09 %	-5.51 %	5.24 %	4.52 %	-6.53 %
Total Assets in million	51,463	46,327	49,026	46,583	44,567
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	1,418	-1,959	-615	-2,499	456
Annual Return On Assets	2.76 %	-4.23 %	-1.25 %	-5.36 %	1.02 %

TEVA's 5 Years Annual ROA >> Back to TEVA Management Effectiveness >> Compare TEVA ROA to its Competitors

Comment on TEVA's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 2.76 % compared to prior year, due to annual net income growth of % to $1,418.00 million, while value of Teva Pharmaceutical Industries Limited's overall assets grew just by 11.09 % to $51,463.00 million, compared to $51,463.00 a year before.

More Return On Assets Ratios
TEVA's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
TEVA's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for TEVA's Competitors
Subscribers only: Roa for Teva Pharmaceutical Industries Limited's Suppliers
Subscribers only: Return On Assets for TEVA's Customers

You may also want to know
TEVA's Roi	TEVA's Inventory Turnover Ratio	TEVA's Growth Rates	TEVA's Dividend Comparisons
	TEVA's Profitability Ratios	TEVA's Asset Turnover Ratio	TEVA's Dividend Growth
TEVA's Roe	TEVA's Valuation Ratios	TEVA's Financial Strength Ratios	TEVA's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector	ROA
The Pennant Group Inc	4.14 %
U S Physical Therapy Inc	4.08 %
Haemonetics Corporation	3.99 %
Henry Schein Inc	3.79 %
Integer Holdings Corporation	3.76 %
Zimmer Biomet Holdings Inc	3.51 %
Ardent Health Inc	3.22 %
Community Health Systems Inc	3.17 %
Vaso Corporation	2.92 %
Collegium Pharmaceutical Inc	2.72 %
National Vision Holdings Inc	2.53 %
Conmed Corporation	2.44 %
Merck and Co Inc	2.42 %
Privia Health Group Inc	2.41 %
Lifestance Health Group Inc	2.33 %
Bio rad Laboratories Inc	2.21 %
Pfizer Inc	2.12 %
Mimedx Group Inc	1.99 %
Revvity Inc	1.97 %
Alkermes Plc	1.96 %
Becton Dickinson And Company	1.77 %
Teva Pharmaceutical Industries Limited	1.77 %
Immucell Corporation	1.76 %
Envista Holdings Corporation	1.69 %
Atricure Inc	1.62 %
Black Hawk Acquisition Corporation	1.56 %
Repligen Corp	1.41 %
Omada Health Inc	1.41 %
Arvinas Inc	1.29 %
Pacira Biosciences inc	1.17 %

Date modified: 2026-08-12T20:54:13+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.